Ventyx Biosciences, Inc.

NasdaqGS:VTYX Stock Report

Market Cap: US$1.0b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Ventyx Biosciences Management

Management criteria checks 3/4

Ventyx Biosciences' CEO is Raju Mohan, appointed in Nov 2018, has a tenure of 7.33 years. total yearly compensation is $1.28M, comprised of 48.5% salary and 51.5% bonuses, including company stock and options. directly owns 3.31% of the company’s shares, worth $33.22M. The average tenure of the management team and the board of directors is 1.6 years and 4.2 years respectively.

Key information

Raju Mohan

Chief executive officer

US$1.3m

Total compensation

CEO salary percentage48.47%
CEO tenure7.3yrs
CEO ownership3.3%
Management average tenure1.6yrs
Board average tenure4.2yrs

Recent management updates

Recent updates

Seeking Alpha • Nov 11

Ventyx Biosciences: Why Caution Should Remain

Summary Ventyx Biosciences reported Phase 2 results for VTX3232, showing strong anti-inflammatory effects as secondary endpoints. VTYX's VTX3232 lowered hsCRP and IL-6, suggesting cardiometabolic benefits, but trial design and biomarker specificity raise concerns about translatability. A short cash runway and heavy reliance on VTX3232's success create significant risk; future trial outcomes will heavily impact the stock. Read the full article on Seeking Alpha
Analysis Article • Sep 23

Is Ventyx Biosciences (NASDAQ:VTYX) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article • May 05

Is Ventyx Biosciences (NASDAQ:VTYX) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Nov 14

We Think Ventyx Biosciences (NASDAQ:VTYX) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Nov 04

Ventyx Biosciences: Ready To Escape "The Crash Cycle"

Summary Based on quatitative factors, Ventyx is similar to other issues I've rated here on Seeking Alpha that have outpaced the market. Because of its extremely low valuation and strong financials, I see obvious potential for Ventyx to outperform the market. Despite past troubles, management actions are addressing issues, though risks include volatility and the risk that drugs will not go commercial. Read the full article on Seeking Alpha
Analysis Article • Jul 12

Is Ventyx Biosciences (NASDAQ:VTYX) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Jul 01

Ventyx Biosciences: Slim Chances In A Fat Market (Rating Downgrade)

Summary Ventyx Biosciences, Inc. is focusing on advancing VTX3232 for obesity and Parkinson's, with early but promising preclinical results in obesity. The drug VTX3232 has shown potential in preclinical trials, but its application in Parkinson’s faces uncertainty due to mixed evidence about the role of NLRP3. Despite a strong balance sheet, Ventyx’s prospects in ulcerative colitis and Crohn's disease face stiff competition and historical clinical failures. Due to the very low odds of clinical and market success, the current low stock prices are seen as a sign to sell rather than buy. Read the full article on Seeking Alpha
Seeking Alpha • Mar 12

Ventyx Pivots To Obesity Amid Transformation

Summary Ventyx's stock plummeted from over $30/share to $2/share after disappointing data for VTX958, prompting workforce reductions. VTX3232 shows promise in preclinical trials for obesity and Parkinson's, with a trial on obesity planned for the second half of the year. Financially, VTYX is stable, with a cash runway extending into the second half of 2026 after recent PIPE financing. Investment recommendation: Hold Ventyx due to high volatility and risk, but it offers potential high returns for diversified portfolios seeking alpha. Read the full article on Seeking Alpha
Analysis Article • Feb 15

Here's Why We're Watching Ventyx Biosciences' (NASDAQ:VTYX) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Jan 18

Ventyx: Too Risky Right Now After Some Poor Data

Summary Ventyx Biosciences has a mid-stage pipeline targeting inflammatory diseases, with lead assets VTX958, VTX002, and VTX2735. Phase 1 data for VTX958 showed high selectivity and excellent safety profile, but phase 2 trial results did not meet internal targets for further development in psoriasis. VTX002 demonstrated positive phase 2 data in ulcerative colitis, achieving primary and secondary endpoints and outperforming other molecules in clinical and endoscopic remission. Read the full article on Seeking Alpha
Analysis Article • Sep 21

Companies Like Ventyx Biosciences (NASDAQ:VTYX) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Jun 07

Ventyx Biosciences (NASDAQ:VTYX) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Feb 20

We're Not Very Worried About Ventyx Biosciences' (NASDAQ:VTYX) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. By way of example, Ventyx...

CEO Compensation Analysis

How has Raju Mohan's remuneration changed compared to Ventyx Biosciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-US$107m

Jun 30 2025n/an/a

-US$119m

Mar 31 2025n/an/a

-US$124m

Dec 31 2024US$1mUS$622k

-US$135m

Sep 30 2024n/an/a

-US$153m

Jun 30 2024n/an/a

-US$171m

Mar 31 2024n/an/a

-US$193m

Dec 31 2023US$9mUS$596k

-US$193m

Sep 30 2023n/an/a

-US$181m

Jun 30 2023n/an/a

-US$158m

Mar 31 2023n/an/a

-US$125m

Dec 31 2022US$4mUS$567k

-US$108m

Sep 30 2022n/an/a

-US$91m

Jun 30 2022n/an/a

-US$73m

Mar 31 2022n/an/a

-US$69m

Dec 31 2021US$15mUS$423k

-US$85m

Sep 30 2021n/an/a

-US$84m

Jun 30 2021n/an/a

-US$79m

Mar 31 2021n/an/a

-US$65m

Dec 31 2020US$68kUS$37k

-US$28m

Compensation vs Market: Raju's total compensation ($USD1.28M) is below average for companies of similar size in the US market ($USD3.38M).

Compensation vs Earnings: Raju's compensation has been consistent with company performance over the past year.

CEO

Raju Mohan (67 yo)

7.3yrs
Tenure
US$1,283,015
Compensation

Dr. Raju S. Mohan, Ph.D. founded Ventyx Biosciences, Inc. in November 2018 and serves as its Chief Executive Officer and Director since November 2018 and serves as its President since November 22, 2023. Dr...

Leadership Team

NamePositionTenureCompensationOwnership
Sheila Gujrathi
Executive Chairperson4.8yrsUS$335.93k0.18%
$ 1.8m
Raju Mohan
Founder7.3yrsUS$1.28m3.31%
$ 33.2m
Matthew Moore
Chief Operating Officer1.8yrsUS$1.92m0%
$ 0
Mark Forman
Chief Medical Officer1.6yrsUS$937.47k0.0084%
$ 84.0k
Roy Gonzales
Senior VP of Finance and Principal Financial & Accounting Officer1.6yrsno data0.0074%
$ 74.3k
John Nuss
Chief Scientific Officer7.2yrsUS$3.89m0.68%
$ 6.9m
Snehal Naik
Senior Vice President of Clinical Development1.2yrsno datano data
Kathy Ogilvie
Senior Vice President of Translational & Nonclinical Research1.2yrsno datano data
Arline Nakanishi
Senior Vice President of Biometrics1.2yrsno datano data
1.6yrs
Average Tenure
57.5yo
Average Age

Experienced Management: VTYX's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Sheila Gujrathi
Executive Chairperson4.8yrsUS$335.93k0.18%
$ 1.8m
Raju Mohan
Founder7.3yrsUS$1.28m3.31%
$ 33.2m
Allison Hulme
Independent Director4.2yrsUS$170.83k0%
$ 0
Somasundaram Subramaniam
Independent Director7.3yrsUS$174.33k0%
$ 0
Alexa Kimball
Member of Scientific Advisory Boardno datano datano data
James Krueger
Member of Scientific Advisory Boardno datano datano data
Bruce Sands
Member of Scientific Advisory Boardno datano datano data
William White
Independent Director4.8yrsUS$172.33k0%
$ 0
Don Frail
Chairman of Scientific Advisory Board1.2yrsno datano data
Onaiza Cadoret-Manier
Independent Director4.2yrsUS$173.83k0%
$ 0
Ted Dawson
Member of Scientific Advisory Board1.2yrsno datano data
Paul Cremer
Member of Scientific Advisory Board1.2yrsno datano data
4.2yrs
Average Tenure
61yo
Average Age

Experienced Board: VTYX's board of directors are considered experienced (4.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/03/05 01:47
End of Day Share Price 2026/03/03 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ventyx Biosciences, Inc. is covered by 3 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hiroshi ShibutaniGoldman Sachs
Michael YeeJefferies LLC
Andrew TsaiJefferies LLC